Literature DB >> 1364826

Heterogeneity of thromboxane A2 (TP-) receptors: evidence from antagonist but not agonist potency measurements.

P M Tymkewycz1, R L Jones, N H Wilson, C G Marr.   

Abstract

1. Thromboxane A2 (TP-) receptors in human, rat and rabbit platelets and in smooth muscle of guinea-pig trachea, rat aorta and rabbit aorta have been characterized by measurement of the potencies of agonists and antagonists having considerable variations in chemical structure. 2. On each washed platelet system, eight prostanoids induced maximal irreversible aggregation (full agonists) and the potency ranking was EP 171 > STA2 > 9,11-azo PGH2 > 9,11-endoxy-10a-homo PGH2 > U-46619 (standard) > PGH2 = 16-p-fluorophenoxy-omega-tetranor PGF2 alpha > 16,16-dimethyl PGF2 alpha. Correlations between the three platelet preparations for both absolute and relative potencies were good. On human platelets, STA2, at concentrations above that required for maximum aggregation, exerted an inhibitory effect which was independent of its interaction with the TP-receptor. 3. Five prostanoids, EP 109, EP 167, EP 204, PTA2 and 16,20-methano PTA2, exhibited partial agonist activity on the platelet and smooth muscle preparations. There was good agreement between absolute potencies on the six preparations; on platelets potency was assessed from shape change measurements, since aggregation, when present, always showed a very shallow concentration-response relationship. The magnitude of the maximum response induced by each compound decreased in the order listed above, to the extent that 16,20-methano PTA2 could be treated as a pure antagonist. 4. With U-46619 as agonist, the pA2 values of seven antagonists were found to be very similar on human and rat platelets. The potency ranking was EP 169 > AH 23848 > EP 092 > ONO 11120 > EP 115 = 16,20-methano PTA2 > BM 13177. There was a similar trend on rabbit platelets but pA2 values were 1.0-1.5 log units smaller; the exception was BM 13177 which had similar affinities. The antagonism produced by EP 169 and AH 23848 was surmountable on rabbit platelets but not on human and rat platelets. 5. None of the antagonists was highly potent on the rabbit aorta (pA2 values < 7.5 by Schild analysis). Affinities on the guinea-pig trachea and the rat aorta were higher and in the same range as those obtained for human and rat platelets. However the correlations of pA2 values between any pair of smooth muscle preparations and between any pair of platelet/smooth muscle preparations were either weak or not significant(P > 0.05). 6. The excellent agreement for both full and partial agonist potencies between the six preparations provides no evidence for TP-receptor subtypes and further suggests that the agonist recognition sites of the TP-receptors could be very similar, if not identical, in nature. In contrast, the different antagonist affinities found in this and other published studies indicate heterogeneity of TP-receptors. However, classification into TP,-, TP2-receptors, etc. on the basis of the limited antagonist data available does not appear appropriate at this time.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1364826      PMCID: PMC1917959          DOI: 10.1111/j.1476-5381.1991.tb12220.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  21 in total

1.  Aggregation of blood platelets by adenosine diphosphate and its reversal.

Authors:  G V BORN
Journal:  Nature       Date:  1962-06-09       Impact factor: 49.962

2.  AH23848: a thromboxane receptor-blocking drug that can clarify the pathophysiologic role of thromboxane A2.

Authors:  R T Brittain; L Boutal; M C Carter; R A Coleman; E W Collington; H P Geisow; P Hallett; E J Hornby; P P Humphrey; D Jack
Journal:  Circulation       Date:  1985-12       Impact factor: 29.690

3.  Interactions of thromboxane A2 analogs and prostaglandins in isolated dog arteries.

Authors:  N Toda; M Nakajima; T Okamura; M Miyazaki
Journal:  J Cardiovasc Pharmacol       Date:  1986 Jul-Aug       Impact factor: 3.105

4.  Prostaglandin E2: effects on aggregation, shape change and cyclic AMP of rat platelets.

Authors:  H Shio; P W Ramwell; S J Jessup
Journal:  Prostaglandins       Date:  1972-01

5.  Competitive antagonism at thromboxane receptors in human platelets.

Authors:  R A Armstrong; R L Jones; V Peesapati; S G Will; N H Wilson
Journal:  Br J Pharmacol       Date:  1985-03       Impact factor: 8.739

6.  Antagonism of the thromboxane-sensitive contractile systems of the rabbit aorta, dog saphenous vein and guinea-pig trachea.

Authors:  R L Jones; V Peesapati; N H Wilson
Journal:  Br J Pharmacol       Date:  1982-07       Impact factor: 8.739

7.  Vitamin K 2,3-epoxide reductase: the basis for stereoselectivity of 4-hydroxycoumarin anticoagulant activity.

Authors:  H H Thijssen; L G Baars; H T Vervoort-Peters
Journal:  Br J Pharmacol       Date:  1988-11       Impact factor: 8.739

8.  GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro.

Authors:  P Lumley; B P White; P P Humphrey
Journal:  Br J Pharmacol       Date:  1989-07       Impact factor: 8.739

9.  Evidence for homogeneity of thromboxane A2 receptor using structurally different antagonists.

Authors:  G T Swayne; J Maguire; J Dolan; P Raval; G Dane; M Greener; D A Owen
Journal:  Eur J Pharmacol       Date:  1988-08-02       Impact factor: 4.432

10.  Peripheral 5-HT2-like receptors. Can they be classified with the available antagonists?

Authors:  P Leff; G R Martin
Journal:  Br J Pharmacol       Date:  1986-07       Impact factor: 8.739

View more
  20 in total

Review 1.  A Review of Prostanoid Receptors: Expression, Characterization, Regulation, and Mechanism of Action.

Authors:  Roger G Biringer
Journal:  J Cell Commun Signal       Date:  2020-09-24       Impact factor: 5.782

2.  Evidence for human thromboxane receptor heterogeneity using a novel series of 9,11-cyclic carbonate derivatives of prostaglandin F2 alpha.

Authors:  A H Krauss; D F Woodward; L L Gibson; C E Protzman; L S Williams; R M Burk; T S Gac; M B Roof; F Abbas; K Marshall; J Senior
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

3.  Prostanoid EP(1)- and TP-receptors involved in the contraction of human pulmonary veins.

Authors:  L Walch; V de Montpreville; C Brink; X Norel
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

4.  Characterization of receptors involved in the direct and indirect actions of prostaglandins E and I on the guinea-pig ileum.

Authors:  R A Lawrence; R L Jones; N H Wilson
Journal:  Br J Pharmacol       Date:  1992-02       Impact factor: 8.739

5.  The cyclo-oxygenase-dependent regulation of rabbit vein contraction: evidence for a prostaglandin E2-mediated relaxation.

Authors:  C Rouaud; M Delaforge; M Anger-Leroy; G Le Filliatre; M Finet; R Hanf
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

6.  Pharmacological studies on prostanoid receptors in the rabbit isolated saphenous vein: a comparison with the rabbit isolated ear artery.

Authors:  S J Lydford; K C McKechnie; I G Dougall
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

Review 7.  Prostanoid receptor antagonists: development strategies and therapeutic applications.

Authors:  R L Jones; M A Giembycz; D F Woodward
Journal:  Br J Pharmacol       Date:  2009-07-15       Impact factor: 8.739

8.  Investigation of the prostaglandin E (EP-) receptor subtype mediating relaxation of the rabbit jugular vein.

Authors:  R A Lawrence; R L Jones
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

9.  Ipratropium bromide protects against bronchoconstriction during bronchoscopy.

Authors:  H Inoue; H Aizawa; S Takata; H Koto; K Matsumoto; M Shigyo; N Hara
Journal:  Lung       Date:  1994       Impact factor: 2.584

10.  Hyperpolarization induced by K+ channel openers inhibits Ca2+ influx and Ca2+ release in coronary artery.

Authors:  T Yanagisawa; T Yamagishi; Y Okada
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.